These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20233649)

  • 1. Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches.
    Keire DA; Mans DJ; Ye H; Kolinski RE; Buhse LF
    J Pharm Biomed Anal; 2010 Sep; 52(5):656-64. PubMed ID: 20233649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate.
    Keire DA; Trehy ML; Reepmeyer JC; Kolinski RE; Ye W; Dunn J; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2010 Mar; 51(4):921-6. PubMed ID: 19959313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class modeling analysis of heparin 1H NMR spectral data using the soft independent modeling of class analogy and unequal class modeling techniques.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Chem; 2011 Feb; 83(3):1030-9. PubMed ID: 21192734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of currently marketed heparin products: key tests for quality assurance.
    Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
    Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of possible economically motivated adulterants in heparin sodium and low molecular weight heparins with a colorimetric microplate based assay.
    Sommers CD; Keire DA
    Anal Chem; 2011 Sep; 83(18):7102-8. PubMed ID: 21819047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive detection of oversulfated chondroitin sulfate in heparin sodium or crude heparin with a colorimetric microplate based assay.
    Sommers CD; Mans DJ; Mecker LC; Keire DA
    Anal Chem; 2011 May; 83(9):3422-30. PubMed ID: 21449571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of currently marketed heparin products: key tests for LMWH quality assurance.
    Ye H; Toby TK; Sommers CD; Ghasriani H; Trehy ML; Ye W; Kolinski RE; Buhse LF; Al-Hakim A; Keire DA
    J Pharm Biomed Anal; 2013 Nov; 85():99-107. PubMed ID: 23917037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data.
    Zang Q; Keire DA; Buhse LF; Wood RD; Mital DP; Haque S; Srinivasan S; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Bioanal Chem; 2011 Aug; 401(3):939-55. PubMed ID: 21678118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and detection of N-sulfonated oversulfated chondroitin sulfate in marketplace heparin.
    Mans DJ; Ye H; Dunn JD; Kolinski RE; Long DS; Phatak NL; Ghasriani H; Buhse LF; Kauffman JF; Keire DA
    Anal Biochem; 2015 Dec; 490():52-4. PubMed ID: 26278168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of SAX-HPLC-CD as a heparin screening strategy.
    Chmielewski AJ; Stanley FE; Stalcup AM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2619-23. PubMed ID: 21831728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitivity visualisation of contaminants in heparin samples by spectral filtering of 1H NMR spectra.
    Rudd TR; Gaudesi D; Lima MA; Skidmore MA; Mulloy B; Torri G; Nader HB; Guerrini M; Yates EA
    Analyst; 2011 Apr; 136(7):1390-8. PubMed ID: 21279244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of currently marketed heparin products: adverse event relevant bioassays.
    Sommers CD; Montpas N; Adam A; Keire DA
    J Pharm Biomed Anal; 2012; 67-68():28-35. PubMed ID: 22591805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of heparin impurities with HPLC-NMR using weak anion exchange chromatography.
    Limtiaco JF; Jones CJ; Larive CK
    Anal Chem; 2009 Dec; 81(24):10116-23. PubMed ID: 19911825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
    Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
    J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (1)H nuclear magnetic resonance spectroscopic analysis for determination of glucuronic and iduronic acids in dermatan sulfate, heparin, and heparan sulfate.
    Sudo M; Sato K; Chaidedgumjorn A; Toyoda H; Toida T; Imanari T
    Anal Biochem; 2001 Oct; 297(1):42-51. PubMed ID: 11567526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy.
    Bigler P; Brenneisen R
    J Pharm Biomed Anal; 2009 May; 49(4):1060-4. PubMed ID: 19211212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples.
    Alban S; Lühn S; Schiemann S; Beyer T; Norwig J; Schilling C; Rädler O; Wolf B; Matz M; Baumann K; Holzgrabe U
    Anal Bioanal Chem; 2011 Jan; 399(2):605-20. PubMed ID: 20824424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin sodium compliance to the new proposed USP monograph: elucidation of a minor structural modification responsible for a process dependent 2.10 ppm NMR signal.
    Mourier PA; Guichard OY; Herman F; Viskov C
    J Pharm Biomed Anal; 2011 Jan; 54(2):337-44. PubMed ID: 20934294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.